Anadis goes over
Friday, 06 June, 2008
Victorian biotech Anadis (ASX: ANX) has sold over $820,000 worth of new shares to its shareholders under its share purchase plan (SPP), raising over $70,000 more than was intended.
The company, which specialises in polyclonal antibodies, said it had originally only intended to raise $750,000 under the SPP, but because of overwhelming interest decided to sell more, raising $823,000.
The new funds will be used to help fund clinical trials, and ultimately commercialise new products, the company said.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
